tradingkey.logo

Akoya Biosciences Inc <AKYA.OQ> expected to post a loss of 16 cents a share - Earnings Preview

ReutersFeb 28, 2025 11:29 AM
  • Akoya Biosciences Inc AKYA.OQ AKYA.O is expected to show a fall in quarterly revenue when it reports results on March 3 (estimated) for the period ending December 31 2024

  • The Marlborough Massachusetts-based company is expected to report a 19.4% decrease in revenue to $21.338 million from $26.49 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Akoya Biosciences Inc is for a loss of 16 cents per share.

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Akoya Biosciences Inc is $3.50​, above​ its last closing price of $1.65. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Sep. 30 2024

-0.20

-0.20

-0.21

Missed

-3.1

Jun. 30 2024

-0.27

-0.27

-0.27

Met

-0.8

Mar. 31 2024

-0.29

-0.29

-0.48

Missed

-66.2​

Dec. 31 2023

-0.27

-0.27

-0.22

Beat

18.1

​​Sep. 30 2023

-0.36

-0.37

-0.26

Beat

28.9

Jun. 30 2023

-0.43

-0.44

-0.46

Missed

-3.9​

Mar. 31 2023

-0.50

-0.48

-0.49

Missed

-1.5

Dec. 31 2022

-0.44

-0.43

-0.50

Missed

-16.3

This summary was machine generated February 28 at 11:29 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI